Get started
Author

Philippe Moris

Randomized, Double‐Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection
2009 · Kent E. Kester, James F. Cummings, et al. · The Journal of Infectious Diseases · 524
PDF
Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only
2006 · S GIANNINI, E HANON, et al. · Vaccine · 496
Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers
2008 · Pierre Vandepapelière, Yves Horsmans, et al. · Vaccine · 218
Improved CD4+ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: A randomized trial
2012 · Isabel Leroux-Roels, Sheron Forgus, et al. · Vaccine · 165
H5N1 Influenza Vaccine Formulated with AS03A Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses
2010 · Philippe Moris, Robbert van der Most, et al. · Journal of Clinical Immunology · 162
PDF
Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting
2015 · Adam Penn-Nicholson, Hennie Geldenhuys, et al. · Vaccine · 139
PDF
Induction and Regulation of T-Cell Immunity by the Novel Tuberculosis Vaccine M72/AS01 in South African Adults
2013 · Cheryl L. Day, Michele Tameris, et al. · American Journal of Respiratory and Critical Care Medicine · 120
Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years
2011 · Mark H. Einstein, Mira Baron, et al. · Human Vaccines · 114
PDF
Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial
2016 · Geert Leroux-Roels, Arnaud Marchant, et al. · Clinical Immunology · 112
PDF
The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans
2009 · Kenneth Von Eschen, Royce Morrison, et al. · Human Vaccines · 107
PDF
Circumsporozoite-Specific T Cell Responses in Children Vaccinated with RTS,S/AS01E and Protection against P falciparum Clinical Malaria
2011 · Ally Olotu, Philippe Moris, et al. · PLoS ONE · 96
PDF
A Randomized, Controlled Dose-Finding Phase II Study of the M72/AS01 Candidate Tuberculosis Vaccine in Healthy PPD-Positive Adults
2013 · Jaime Montoya, Juan Antonio Solon, et al. · Journal of Clinical Immunology · 93
PDF
Ad35.CS.01 - RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults
2015 · Christian F. Ockenhouse, Jason Regules, et al. · PLoS ONE · 92
PDF
Protective Immunity Induced with the RTS,S/AS Vaccine Is Associated with IL-2 and TNF-α Producing Effector and Central Memory CD4+ T Cells
2011 · Joanne M. Lumsden, Robert J. Schwenk, et al. · PLoS ONE · 85
PDF
Antigen-Specific IL-2 Secretion Correlates with NK Cell Responses after Immunization of Tanzanian Children with the RTS,S/AS01 Malaria Vaccine
2012 · Amir Horowitz, Julius C R Hafalla, et al. · The Journal of Immunology · 84
Safety and immunogenicity of the M72/AS01 E candidate tuberculosis vaccine in adults with tuberculosis: A phase II randomised study
2016 · Paul Gillard, Pan-Chyr Yang, et al. · Tuberculosis · 79
PDF
Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-Adjuvanted Prepandemic Candidate Influenza Vaccines in Children Aged 3 to 9 Years
2010 · Javier Díez-Domingo, Maria Garcés-Sanchez, et al. · The Pediatric Infectious Disease Journal · 75
PDF
Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines
2014 · Geert Leroux-Roels, Isabel Leroux-Roels, et al. · Human Vaccines & Immunotherapeutics · 66
PDF
T Cell Responses to the RTS,S/AS01E and RTS,S/AS02D Malaria Candidate Vaccines Administered According to Different Schedules to Ghanaian Children
2011 · Daniel Ansong, Kwaku P. Asante, et al. · PLoS ONE · 66
PDF
Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03 B adjuvant: Results of a randomized phase I trial
2015 · Jack Levy, Laurent Licini, et al. · Human Vaccines & Immunotherapeutics · 64
PDF
Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: An open-label randomized controlled trial
2014 · Olubukola T. Idoko, Olumuyiwa A. Owolabi, et al. · Tuberculosis · 64
Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: Follow-up through Month 48 in a Phase III randomized study
2014 · Mark H Einstein, Myron J Levin, et al. · Human Vaccines & Immunotherapeutics · 63
Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: Randomised, controlled trials
2013 · Isabel Leroux-Roels, Jeanne-Marie Devaster, et al. · Vaccine · 62
A Randomized, Controlled Safety, and Immunogenicity Trial of the M72/AS01 Candidate Tuberculosis Vaccine in HIV-Positive Indian Adults
2016 · Nagalingeswaran Kumarasamy, Selvamuthu Poongulali, et al. · Medicine · 58
Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy
2014 · Eleonora G. Thacher, Matthias Cavassini, et al. · AIDS · 57
Works count: 64
Citation count: 4,192
H-index: 36
I10-index: 51
Year
Topic
Type